Symbols / VSTM $5.48 -2.66% Verastem, Inc.

Healthcare • Biotechnology • United States • NCM
VSTM Chart
About

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 481.34M
Enterprise Value 376.69M Income -209.47M Sales 30.91M
Book/sh 0.74 Cash/sh 2.33 Dividend Yield —
Payout 0.00% Employees 102 IPO —
P/E — Forward P/E -4.63 PEG —
P/S 15.57 P/B 7.45 P/C —
EV/EBITDA -2.22 EV/Sales 12.19 Quick Ratio 2.96
Current Ratio 3.09 Debt/Eq 152.40 LT Debt/Eq —
EPS (ttm) -3.02 EPS next Y -1.18 EPS Growth —
Revenue Growth — Earnings 2026-05-05 ROA -61.11%
ROE -14.80% ROIC — Gross Margin 85.12%
Oper. Margin -236.53% Profit Margin 0.00% Shs Outstand 87.84M
Shs Float 75.06M Short Float 20.38% Short Ratio 11.45
Short Interest — 52W High 11.25 52W Low 4.01
Beta 0.43 Avg Volume 2.01M Volume 1.32M
Target Price $16.38 Recom Strong_buy Prev Close $5.63
Price $5.48 Change -2.66%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$16.38
Mean price target
2. Current target
$5.48
Latest analyst target
3. DCF / Fair value
$-16.87
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.48
Low
$14.00
High
$19.00
Mean
$16.38

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-09-09 reit BTIG Buy → Buy $20
2025-08-08 main RBC Capital Outperform → Outperform $13
2025-06-25 main RBC Capital Outperform → Outperform $12
2025-05-09 main HC Wainwright & Co. Buy → Buy $14
2025-04-10 init Jefferies — → Buy $15
2025-04-09 main Mizuho Outperform → Outperform $8
2025-03-24 main Guggenheim Buy → Buy $14
2025-03-24 main HC Wainwright & Co. Buy → Buy $10
2025-03-21 main RBC Capital Outperform → Outperform $14
2025-01-31 main B. Riley Securities Buy → Buy $9
2025-01-24 reit Guggenheim Buy → Buy —
2025-01-07 main RBC Capital Outperform → Outperform $16
2024-12-19 main Mizuho Outperform → Outperform $9
2024-12-19 reit HC Wainwright & Co. Buy → Buy $7
2024-08-13 main Truist Securities Buy → Buy $15
2024-08-12 main HC Wainwright & Co. Buy → Buy $7
2024-08-09 main RBC Capital Outperform → Outperform $13
2024-07-24 main B. Riley Securities Buy → Buy $7
2024-07-08 main Truist Securities Buy → Buy $18
2024-05-29 main Alliance Global Partners Buy → Buy $20
News
RSS: Latest VSTM news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-20 CALKINS DANIEL Chief Financial Officer — 57 $5.74 $327
2026-02-04 PATERSON DANIEL W Chief Executive Officer — 970 $6.69 $6,489
2026-01-21 PATERSON DANIEL W Chief Executive Officer — 213,785 $0.00 $0
2026-01-21 CALKINS DANIEL Chief Financial Officer — 16,665 $0.00 $0
2026-01-12 PATERSON DANIEL W Chief Executive Officer — 10,321 $7.16 $73,898
2026-01-12 CALKINS DANIEL Chief Financial Officer — 5,039 $7.16 $36,079
2025-12-24 CALKINS DANIEL Chief Financial Officer — 80 $7.86 $629
2025-12-16 GAGNON ROBERT E Director — 283 $9.14 $2,587
2025-12-16 PATERSON DANIEL W Chief Executive Officer — 393 $9.14 $3,592
2025-12-16 STUGLIK BRIAN M Director — 592 $9.14 $5,411
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
30.91
+209.14%
10.00
0.00
-100.00%
2.60
Operating Revenue
30.91
+209.14%
10.00
0.00
-100.00%
2.60
Cost Of Revenue
5.30
0.00
0.00
0.00
Reconciled Cost Of Revenue
5.30
0.00
0.00
0.00
Gross Profit
25.62
+156.16%
10.00
0.00
-100.00%
2.60
Operating Expense
195.75
+56.65%
124.96
+35.70%
92.08
+21.91%
75.53
Research And Development
114.60
+40.90%
81.33
+32.56%
61.36
+21.36%
50.56
Selling General And Administration
81.15
+86.02%
43.62
+41.96%
30.73
+23.04%
24.98
Total Expenses
201.04
+60.89%
124.96
+35.70%
92.08
+21.91%
75.53
Operating Income
-170.13
-47.99%
-114.96
-24.84%
-92.08
-26.25%
-72.94
Total Operating Income As Reported
-170.13
-47.99%
-114.96
-24.84%
-92.08
-26.25%
-72.94
EBITDA
-207.60
-64.94%
-125.86
-51.34%
-83.17
-16.22%
-71.56
Normalized EBITDA
-178.29
-67.07%
-106.72
-28.32%
-83.17
-16.22%
-71.56
Reconciled Depreciation
0.73
+2700.00%
0.03
-58.06%
0.06
-47.46%
0.12
EBIT
-208.33
-65.49%
-125.89
-51.26%
-83.23
-16.12%
-71.67
Total Unusual Items
-29.32
-53.10%
-19.15
0.00
0.00
Total Unusual Items Excluding Goodwill
-29.32
-53.10%
-19.15
0.00
0.00
Special Income Charges
-1.83
0.00
0.00
0.00
Other Special Charges
1.83
—
—
—
Net Income
-209.47
-60.35%
-130.64
-49.53%
-87.37
-18.36%
-73.81
Pretax Income
-209.47
-60.57%
-130.45
-49.31%
-87.37
-18.36%
-73.81
Net Non Operating Interest Income Expense
2.93
+809.44%
-0.41
-119.90%
2.08
+325.05%
-0.92
Interest Expense Non Operating
1.14
-75.05%
4.56
+10.22%
4.14
+93.68%
2.14
Net Interest Income
2.93
+809.44%
-0.41
-119.90%
2.08
+325.05%
-0.92
Interest Expense
1.14
-75.05%
4.56
+10.22%
4.14
+93.68%
2.14
Interest Income Non Operating
4.07
-1.95%
4.15
-33.23%
6.21
+411.44%
1.22
Interest Income
4.07
-1.95%
4.15
-33.23%
6.21
+411.44%
1.22
Other Income Expense
-42.27
-180.26%
-15.08
-670.89%
2.64
+5521.28%
0.05
Other Non Operating Income Expenses
-12.95
-418.59%
4.07
+53.90%
2.64
+5521.28%
0.05
Gain On Sale Of Security
-27.49
-43.57%
-19.15
—
—
Tax Provision
0.00
-100.00%
0.18
0.00
0.00
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-4.02
0.00
0.00
Net Income Including Noncontrolling Interests
-209.47
-60.35%
-130.64
-49.53%
-87.37
-18.36%
-73.81
Net Income From Continuing Operation Net Minority Interest
-209.47
-60.35%
-130.64
-49.53%
-87.37
-18.36%
-73.81
Net Income From Continuing And Discontinued Operation
-209.47
-60.35%
-130.64
-49.53%
-87.37
-18.36%
-73.81
Net Income Continuous Operations
-209.47
-60.35%
-130.64
-49.53%
-87.37
-18.36%
-73.81
Normalized Income
-180.15
-55.96%
-115.51
-32.21%
-87.37
-18.36%
-73.81
Net Income Common Stockholders
-209.47
-60.35%
-130.64
-49.53%
-87.37
-18.36%
-73.81
Diluted EPS
—
-3.66
+7.58%
-3.96
+13.35%
-4.57
Basic EPS
—
-3.66
+7.58%
-3.96
+13.35%
-4.57
Basic Average Shares
—
35.71
+61.93%
22.05
+36.66%
16.14
Diluted Average Shares
—
35.71
+61.93%
22.05
+36.66%
16.14
Diluted NI Availto Com Stockholders
-209.47
-60.35%
-130.64
-49.53%
-87.37
-18.36%
-73.81
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
246.44
+142.71%
101.54
-32.18%
149.72
+57.51%
95.05
Current Assets
223.41
+135.27%
94.96
-33.91%
143.68
+54.71%
92.87
Cash Cash Equivalents And Short Term Investments
213.80
+140.72%
88.82
-35.23%
137.13
+56.02%
87.89
Cash And Cash Equivalents
204.99
+130.80%
88.82
+14.00%
77.91
+3.97%
74.93
Other Short Term Investments
8.81
0.00
-100.00%
59.22
+356.91%
12.96
Receivables
0.20
+0.00%
0.20
0.00
-100.00%
0.03
Accounts Receivable
—
0.20
0.00
-100.00%
0.03
Other Receivables
0.20
+0.00%
0.20
—
—
Inventory
1.83
0.00
—
—
Raw Materials
0.00
0.00
—
—
Work In Process
1.80
0.00
—
—
Finished Goods
0.04
0.00
—
—
Prepaid Assets
—
—
—
4.95
Other Current Assets
7.58
+27.49%
5.94
-9.31%
6.55
+32.52%
4.95
Total Non Current Assets
23.03
+250.14%
6.58
+8.96%
6.04
+176.88%
2.18
Net PPE
0.49
-65.83%
1.44
+18.96%
1.21
-35.78%
1.88
Gross PPE
2.11
-30.83%
3.06
+9.11%
2.80
-17.91%
3.41
Accumulated Depreciation
-1.62
-0.25%
-1.62
-1.63%
-1.59
-4.05%
-1.53
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.48
-1.86%
1.50
+1.90%
1.48
+0.00%
1.48
Other Properties
0.49
-65.05%
1.41
+19.27%
1.18
-34.15%
1.79
Leases
0.15
+0.00%
0.15
+0.00%
0.15
+0.00%
0.15
Goodwill And Other Intangible Assets
16.43
0.00
—
—
Other Intangible Assets
16.43
—
—
—
Investments And Advances
—
—
—
—
Other Non Current Assets
6.11
+18.91%
5.14
+6.46%
4.83
+1514.72%
0.30
Total Liabilities Net Minority Interest
189.25
+45.09%
130.43
+41.24%
92.34
+93.76%
47.66
Current Liabilities
72.27
+133.33%
30.97
+17.41%
26.38
+21.77%
21.66
Payables And Accrued Expenses
55.57
+134.14%
23.73
+16.82%
20.32
+26.66%
16.04
Payables
12.45
+209.19%
4.03
-43.96%
7.18
+46.58%
4.90
Accounts Payable
12.45
+209.19%
4.03
-43.96%
7.18
+46.58%
4.90
Current Accrued Expenses
43.12
+118.81%
19.71
+50.07%
13.13
+17.89%
11.14
Pensionand Other Post Retirement Benefit Plans Current
10.86
+73.90%
6.25
+30.21%
4.80
+24.77%
3.84
Current Debt And Capital Lease Obligation
5.84
+486.83%
0.99
+5.74%
0.94
-11.97%
1.07
Current Debt
5.30
—
—
0.28
Other Current Borrowings
5.30
—
—
0.28
Current Capital Lease Obligation
0.54
-46.23%
0.99
+5.74%
0.94
+18.51%
0.79
Current Deferred Liabilities
—
0.00
-100.00%
0.33
-53.94%
0.71
Total Non Current Liabilities Net Minority Interest
116.98
+17.61%
99.46
+50.78%
65.96
+153.75%
26.00
Long Term Debt And Capital Lease Obligation
81.33
+97.12%
41.26
+1.58%
40.62
+56.24%
26.00
Long Term Debt
81.33
+99.71%
40.72
+1.59%
40.09
+63.44%
24.53
Long Term Capital Lease Obligation
0.00
-100.00%
0.54
+0.94%
0.53
-63.95%
1.47
Preferred Securities Outside Stock Equity
0.00
0.00
-100.00%
25.35
0.00
Stockholders Equity
57.20
+297.96%
-28.89
-150.36%
57.37
+21.07%
47.39
Common Stock Equity
57.20
+297.96%
-28.89
-150.36%
57.37
+21.07%
47.39
Capital Stock
0.01
+100.00%
0.00
+33.33%
0.00
+50.00%
0.00
Common Stock
0.01
+100.00%
0.00
+33.33%
0.00
+50.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
77.74
+73.59%
44.78
+77.15%
25.28
+51.28%
16.71
Ordinary Shares Number
77.74
+73.59%
44.78
+77.15%
25.28
+51.28%
16.71
Additional Paid In Capital
1,216.96
+31.33%
926.63
+5.03%
882.25
+12.40%
784.91
Retained Earnings
-1,165.00
-21.92%
-955.53
-15.84%
-824.89
-11.85%
-737.52
Gains Losses Not Affecting Retained Earnings
5.23
0.00
-100.00%
0.01
0.00
Other Equity Adjustments
5.23
—
0.01
—
Total Equity Gross Minority Interest
57.20
+297.96%
-28.89
-150.36%
57.37
+21.07%
47.39
Total Capitalization
138.53
+1070.88%
11.83
-87.86%
97.46
+35.52%
71.92
Working Capital
151.15
+136.21%
63.99
-45.45%
117.30
+64.73%
71.21
Invested Capital
143.83
+1115.71%
11.83
-87.86%
97.46
+35.00%
72.19
Total Debt
87.17
+106.30%
42.25
+1.68%
41.56
+53.55%
27.07
Capital Lease Obligations
0.54
-65.03%
1.53
+4.01%
1.47
-35.03%
2.26
Net Tangible Assets
40.77
+241.11%
-28.89
-150.36%
57.37
+21.07%
47.39
Tangible Book Value
40.77
+241.11%
-28.89
-150.36%
57.37
+21.07%
47.39
Derivative Product Liabilities
35.65
-38.75%
58.20
0.00
—
Interest Payable
0.00
-100.00%
0.32
+0.00%
0.32
+64.58%
0.19
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-137.51
-31.25%
-104.77
-21.18%
-86.46
-35.79%
-63.67
Cash Flow From Continuing Operating Activities
-137.51
-31.25%
-104.77
-21.18%
-86.46
-35.79%
-63.67
Net Income From Continuing Operations
-209.47
-60.35%
-130.64
-49.53%
-87.37
-18.36%
-73.81
Depreciation Amortization Depletion
0.73
+2700.00%
0.03
-58.06%
0.06
-47.46%
0.12
Depreciation
0.03
+15.38%
0.03
-58.06%
0.06
-47.46%
0.12
Amortization Cash Flow
0.70
0.00
0.00
0.00
Depreciation And Amortization
0.73
+2700.00%
0.03
-58.06%
0.06
-47.46%
0.12
Amortization Of Intangibles
0.70
0.00
0.00
0.00
Other Non Cash Items
6.51
+248.96%
-4.37
-7.66%
-4.06
-5583.78%
0.07
Stock Based Compensation
9.40
+28.08%
7.34
+25.29%
5.86
-3.09%
6.05
Operating Gains Losses
29.32
+53.10%
19.15
—
—
Gain Loss On Investment Securities
27.49
+43.57%
19.15
—
—
Change In Working Capital
26.00
+599.41%
3.72
+488.51%
-0.96
-124.54%
3.90
Change In Receivables
-8.81
-4306.50%
-0.20
-745.16%
0.03
-93.61%
0.48
Changes In Account Receivables
-8.81
0.00
-100.00%
0.03
-93.61%
0.48
Change In Inventory
-1.83
0.00
0.00
0.00
Change In Prepaid Assets
-2.60
-337.08%
-0.60
+89.77%
-5.83
-883.06%
0.74
Change In Payables And Accrued Expense
39.26
+710.89%
4.84
-7.28%
5.22
+166.24%
1.96
Change In Accrued Expense
30.83
+285.46%
8.00
+172.26%
2.94
+560.50%
-0.64
Change In Payable
8.42
+366.69%
-3.16
-238.33%
2.28
-12.16%
2.60
Change In Account Payable
8.42
+366.69%
-3.16
-238.33%
2.28
-12.16%
2.60
Change In Other Working Capital
—
-0.33
+14.62%
-0.38
-153.94%
0.71
Change In Other Current Assets
—
—
—
0.00
Change In Other Current Liabilities
—
—
—
0.00
Investing Cash Flow
-9.62
-116.05%
59.97
+234.93%
-44.45
-167.16%
66.19
Cash Flow From Continuing Investing Activities
-9.62
-116.05%
59.97
+234.93%
-44.45
-167.16%
66.19
Net PPE Purchase And Sale
0.00
+100.00%
-0.03
0.00
0.00
Purchase Of PPE
0.00
+100.00%
-0.03
0.00
0.00
Capital Expenditure
-9.62
-34271.43%
-0.03
—
—
Net Investment Purchase And Sale
0.00
-100.00%
60.00
+234.99%
-44.45
-167.16%
66.19
Purchase Of Investment
0.00
0.00
+100.00%
-96.45
-441.38%
-17.82
Sale Of Investment
0.00
-100.00%
60.00
+15.38%
52.00
-38.10%
84.00
Net Intangibles Purchase And Sale
-9.62
0.00
0.00
—
Purchase Of Intangibles
-9.62
0.00
0.00
—
Financing Cash Flow
263.31
+380.64%
54.78
-59.18%
134.19
+159.14%
51.78
Cash Flow From Continuing Financing Activities
263.31
+380.64%
54.78
-59.18%
134.19
+159.14%
51.78
Net Issuance Payments Of Debt
32.42
+21714.00%
-0.15
-101.03%
14.62
-39.46%
24.15
Issuance Of Debt
75.00
0.00
-100.00%
14.92
-38.22%
24.15
Repayment Of Debt
-42.58
-28286.00%
-0.15
+50.00%
-0.30
0.00
Long Term Debt Issuance
75.00
0.00
-100.00%
14.92
-38.22%
24.15
Long Term Debt Payments
-42.58
-28286.00%
-0.15
+50.00%
-0.30
0.00
Net Long Term Debt Issuance
32.42
+21714.00%
-0.15
-101.03%
14.62
-39.46%
24.15
Net Common Stock Issuance
196.98
+1285.11%
14.22
-84.44%
91.42
+234.21%
27.35
Common Stock Payments
—
—
—
—
Cash Dividends Paid
—
—
—
0.00
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
33.91
-16.71%
40.71
+71322.81%
0.06
-79.79%
0.28
Net Other Financing Charges
—
—
—
—
Changes In Cash
116.17
+1063.70%
9.98
+203.71%
3.29
-93.95%
54.30
Beginning Cash Position
89.06
+12.62%
79.08
+4.34%
75.79
+252.62%
21.49
End Cash Position
205.23
+130.44%
89.06
+12.62%
79.08
+4.34%
75.79
Free Cash Flow
-147.13
-40.40%
-104.80
-21.21%
-86.46
-35.79%
-63.67
Interest Paid Supplemental Data
6.36
+68.63%
3.77
+12.29%
3.36
+118.82%
1.54
Income Tax Paid Supplemental Data
0.18
0.00
0.00
—
Common Stock Issuance
196.98
+1285.11%
14.22
-84.44%
91.42
+234.21%
27.35
Interest Paid CFF
—
—
—
0.00
Issuance Of Capital Stock
196.98
+1285.11%
14.22
-88.10%
119.52
+336.93%
27.35
Net Preferred Stock Issuance
0.00
0.00
-100.00%
28.10
0.00
Preferred Stock Issuance
0.00
0.00
-100.00%
28.10
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category